| Literature DB >> 31276792 |
Joseph R Patterson1, Megan F Duffy2, Christopher J Kemp3, Jacob W Howe3, Timothy J Collier4, Anna C Stoll5, Kathryn M Miller2, Pooja Patel3, Nathan Levine6, Darren J Moore6, Kelvin C Luk7, Sheila M Fleming8, Nicholas M Kanaan4, Katrina L Paumier3, Omar M A El-Agnaf9, Caryl E Sortwell4.
Abstract
Animal models that accurately recapitulate the accumulation of alpha-synuclein (α-syn) inclusions, progressive neurodegeneration of the nigrostriatal system and motor deficits can be useful tools for Parkinson's disease (PD) research. The preformed fibril (PFF) synucleinopathy model in rodents generally displays these PD-relevant features, however, the magnitude and predictability of these events is far from established. We therefore sought to optimize the magnitude of α-syn accumulation and nigrostriatal degeneration, and to understand the time course of both. Rats were injected unilaterally with different quantities of α-syn PFFs (8 or 16 μg of total protein) into striatal sites selected to concentrate α-syn inclusion formation in the substantia nigra pars compacta (SNpc). Rats displayed an α-syn PFF quantity-dependent increase in the magnitude of ipsilateral SNpc inclusion formation at 2 months and bilateral loss of nigral dopamine neurons at 6 months. Unilateral 16 μg PFF injection also resulted in modest sensorimotor deficits in forelimb adjusting steps associated with degeneration at 6 months. Bilateral injection of 16 μg α-syn PFFs resulted in symmetric bilateral degeneration equivalent to the ipsilateral nigral degeneration observed following unilateral 16 μg PFF injection (~50% loss). Bilateral PFF injections additionally resulted in alterations in several gait analysis parameters. These α-syn PFF parameters can be applied to generate a reproducible synucleinopathy model in rats with which to study pathogenic mechanisms and vet potential disease-modifying therapies.Entities:
Keywords: Alpha-Synuclein; Parkinson's disease; Preformed fibrils; Synucleinopathy
Year: 2019 PMID: 31276792 PMCID: PMC6701176 DOI: 10.1016/j.nbd.2019.104525
Source DB: PubMed Journal: Neurobiol Dis ISSN: 0969-9961 Impact factor: 5.996